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Introduction {#bjs550240-sec-0005}
============

RCTs are considered the best quality evidence for the effectiveness of therapeutic interventions. Surgeons may use this evidence to inform patients to reach informed consent and facilitate shared decision‐making. Surgeons need to communicate clearly the benefits and harms of possible treatments so that patients can understand and weigh these options and express a preference[1](#bjs550240-bib-0001){ref-type="ref"}. Surgeons should therefore be able to rely on clear and complete information about trial results.

Interpreting the results of an RCT remains challenging, however, as reporting outcomes may lack transparency. The CONSORT statement[2](#bjs550240-bib-0002){ref-type="ref"}, [3](#bjs550240-bib-0003){ref-type="ref"} was developed in the late 1990s to promote complete, clear and uniform reporting of RCTs. An extended version[4](#bjs550240-bib-0004){ref-type="ref"}, published in 2004, added ten recommendations about harm‐related data. Although widely supported, evidence shows there is still inadequate reporting in RCTs[5](#bjs550240-bib-0005){ref-type="ref"}, [6](#bjs550240-bib-0006){ref-type="ref"}.

The aim of this systematic review was to assess the reporting of data on the benefits and harms in a recent representative sample of surgical RCTs in leading medical journals, in order to appreciate whether reported outcomes were easily interpretable and applicable in clinical practice when treatment decisions have to be made.

Methods {#bjs550240-sec-0006}
=======

This review was conducted according to the PRISMA statement[7](#bjs550240-bib-0007){ref-type="ref"}.

*Journal Citation Reports* was used to identify the top five leading general medical journals and the top ten surgical journals, ranked by impact factors in 2015 (*Table* [1](#bjs550240-tbl-0001){ref-type="table"}). A literature search was conducted in the MEDLINE database using PubMed. As only RCTs published within the specific journals were under consideration, the search did not extend to other databases; all the journals were available and traceable through PubMed.

###### 

Characteristics of included journals

  Journal                                                   Impact factor 2015   CONSORT endorsement   No. of included trials   Modified CONSORT score of included trials[\*](#bjs550240-note-0002){ref-type="fn"}
  -------------------------------------------------------- -------------------- --------------------- ------------------------ ------------------------------------------------------------------------------------
  *Annals of Surgery*                                              8·6                   Yes                     23                                                47 (24--59)
  *American Journal of Transplantation*                            5·7                   Yes                     1                                                      40
  *Journal of the American Medical Association Surgery*            5·7                   Yes                     1                                                      57
  *British Journal of Surgery*                                     5·6                   Yes                     26                                                50 (31--61)
  *Journal of Bone and Joint Surgery -- American Volume*           5·2                   No                      15                                                48 (32--56)
  *Journal of the American College of Surgeons*                    4·3                   Yes                     2                                                 61 (59--63)
  *New England Journal of Medicine*                                59·6                  Yes                     10                                                54 (39--61)
  *Lancet*                                                         44·0                  Yes                     6                                                 55 (47--63)
  *Journal of the American Medical Association*                    37·7                  Yes                     4                                                 52 (38--63)

Values are median (range).

RCTs including surgical patients and published between January 2005 and January 2017 were eligible. This time interval reflected the publication of the CONSORT extension for harms in 2004. The last search was conducted in January 2017. RCTs that compared a surgical treatment with another surgical or non‐surgical treatment were sought. The search was limited using RCT as publication type along with the following terms, combined using 'OR': 'Surgical Procedures, Operative'\[Mesh\], 'excision\*'\[tiab\], 'postoperation\*'\[tiab\], 'postoperative'\[tiab\], 'resection\*'\[tiab\], and 'surg\*'\[tiab\].

Study selection {#bjs550240-sec-0007}
---------------

It was planned to include a sample of about 100 RCTs. Based on the screening of a pilot sample of 100 eligible RCTs, eight matched the inclusion criteria. Therefore, 1200 RCTs were selected randomly from the initial set of eligible trials to arrive at the intended 100 RCTs. Studies on patients younger than 18 years, non‐human studies, pilot studies, non‐RCTs, and RCTs in ophthalmology, gynaecology and otorhinolaryngology (being not exclusively surgical specialties) were excluded.

Two reviewers conducted the screening of titles and abstracts of the eligible studies independently. Any disagreements were resolved by a third reviewer. Two reviewers then performed the full‐text screening independently. EndNote X7 (<https://endnote.com/>), Covidence (The Cochrane Collaboration; <https://www.covidence.org/home>) and Excel® 2010 (Microsoft, Redmond, Washington, USA) were used during the process of study selection.

Critical appraisal {#bjs550240-sec-0008}
------------------

The revised version of the CONSORT statement and the CONSORT extension for harms were used to evaluate completeness of reporting RCTs[2](#bjs550240-bib-0002){ref-type="ref"}, [4](#bjs550240-bib-0004){ref-type="ref"}, [8](#bjs550240-bib-0008){ref-type="ref"}, [9](#bjs550240-bib-0009){ref-type="ref"}, excluding those unrelated to surgical intervention[10](#bjs550240-bib-0010){ref-type="ref"}. The revised CONSORT statement provides a checklist of 22 items, and the CONSORT extension for harms checklist contains ten additional items. The reviewers discussed both checklists beforehand in order to have the same understanding of each item. This resulted in a combined checklist of 35 items (*Table* [2](#bjs550240-tbl-0002){ref-type="table"}). Two reviewers independently scored the items. Discrepancies were resolved by discussion.

###### 

Modified CONSORT checklist and adherence in the 88 trials

  Item   Description                                                                                                                                                                             No description   Inadequate description   Adequate description
  ------ -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------- ------------------------ ----------------------
  1      Collected data on harms and benefits stated in title and abstract                                                                                                                           0 (0)               34 (39)                 54 (61)
  2      Collected data on harms and benefits stated in the introduction                                                                                                                             0 (0)               62 (71)                 26 (30)
  3      Explicit definition of eligibility criteria for participants                                                                                                                                0 (0)                1 (1)                  87 (99)
  4      Description of settings/locations where data were collected                                                                                                                                 1 (1)               35 (40)                 52 (59)
  5      Details of intervention intended for each group and how/when they were administered                                                                                                         3 (3)                6 (7)                  79 (90)
  6      Specific objectives and hypotheses                                                                                                                                                          0 (0)                3 (3)                  85 (97)
  7      Clearly defined primary and secondary outcome measures, and (when applicable) any methods used to enhance quality of measurements                                                           0 (0)               20 (23)                 68 (77)
  8      List addressed adverse events with definitions for each                                                                                                                                    13 (15)              34 (39)                 41 (47)
  9      Clarify how harms‐related data were collected                                                                                                                                              17 (19)              21 (24)                 50 (57)
  10     How sample size was determined and (when applicable) explanation of any interim analyses and stopping rules                                                                                12 (14)               0 (0)                  76 (86)
  11     Method used to generate the random allocation sequence, including details of any restriction                                                                                               20 (23)               4 (5)                  64 (73)
  12     Method used to implement the random allocation sequence, clarifying whether sequence was concealed until interventions were assigned                                                       21 (24)               3 (3)                  64 (73)
  13     Who generated the allocation sequence, who enrolled participants, who assigned participants to their groups                                                                                53 (60)               4 (5)                  31 (35)
  14     Details of blinding of subjects                                                                                                                                                            49 (56)               0 (0)                  39 (44)
  15     Details of blinding of treatment providers                                                                                                                                                 55 (63)               0 (0)                  33 (38)
  16     Details of blinding of assessors                                                                                                                                                           43 (49)               1 (1)                  44 (50)
  17     Details of blinding of data analysts                                                                                                                                                       64 (73)               0 (0)                  24 (27)
  18     How the success of masking was assessed                                                                                                                                                    66 (75)               0 (0)                  22 (25)
  19     Statistical methods used to compare groups for primary outcome(s); methods for additional analyses                                                                                          0 (0)                7 (8)                  81 (92)
  20     Describe plans for presenting and analysing information on harms                                                                                                                           23 (26)              11 (13)                 54 (61)
  21     Flow chart describing patient numbers at different stages                                                                                                                                  22 (25)               1 (1)                  65 (74)
  22     Flow of participants described in text; describe protocol deviations from study as planned together with reasons                                                                            0 (0)               24 (27)                 64 (73)
  23     Dates defining the periods of recruitment and follow‐up                                                                                                                                     5 (6)                2 (2)                  81 (92)
  24     Describe withdrawals due to harms and their experiences with allocated treatment                                                                                                           35 (40)              12 (14)                 41 (47)
  25     Baseline demographic and clinical characteristics of each group                                                                                                                             1 (1)                6 (7)                  81 (92)
  26     Number of participants in each group included in each analysis; use of intention‐to‐treat principle. State results in absolute numbers when feasible                                       27 (31)               1 (1)                  60 (68)
  27     Provide the denominators for analyses on harms                                                                                                                                             11 (13)              20 (23)                 57 (65)
  28     Complete reporting of results and estimated effect size and its precision                                                                                                                   0 (0)               15 (17)                 73 (83)
  29     Multiple testing and corrections, indicating those prespecified and those exploratory                                                                                                      16 (18)               0 (0)                  72 (82)
  30     All important adverse events or side‐effects in each intervention group/patient                                                                                                            10 (11)              21 (24)                 57 (65)
  31     Present the absolute risk per arm and per adverse event type, grade, and seriousness, and present appropriate metrics for recurrent events, continuous variables and scale variables       11 (13)              33 (38)                 44 (50)
  32     Describe any subgroup analyses and exploratory analyses for harms                                                                                                                          69 (78)               2 (2)                  17 (19)
  33     Balanced discussion of own study results                                                                                                                                                    0 (0)               34 (39)                 54 (61)
  34     Balanced discussion of generalizability of study results                                                                                                                                   78 (89)               0 (0)                  10 (11)
  35     Balanced discussion in comparison with overall evidence                                                                                                                                     0 (0)               32 (36)                 56 (64)

Values in parentheses are percentages.

In addition, the number needed to treat (NNT) and number needed to harm (NNH) were scored, as these numbers are considered as clinically useful measures because of their comprehensibility[11](#bjs550240-bib-0011){ref-type="ref"}, [12](#bjs550240-bib-0012){ref-type="ref"}. The 'possible impact of funding on results' was scored as adequate if it was clear from the trial description that it had received unrestricted funding (the sponsor had had no influence on the trial conduct, data collection and analysis, interpretation of the data or writing of the manuscript). Judgement of some items, such as blinding, was given the benefit of the doubt and scored as adequate if this was clear implicitly from the text, even though not stated as such. Similarly, the (in)adequacy of the description of generalizability and comparison with overall evidence was judged with leniency.

Data extraction {#bjs550240-sec-0009}
---------------

A predefined, structured, data extraction form was composed to extract the study characteristics. These were: first author, journal, country of study, year of publication, number of contributing centres, involvement of a statistician or epidemiologist, surgical subspecialty, nature of interventions (surgical *versus* surgical, or surgical *versus* non‐surgical), patient characteristics, types of intervention, sample size, follow‐up period, types and total number of outcomes. One reviewer extracted the data, which was checked by a second reviewer independently. Discrepancies were resolved by discussion.

Only data for up to two 'primary' benefits (desired outcomes as primary outcomes), up to three 'secondary' benefits, up to two 'primary' harms (outcomes to be avoided, used as primary outcomes) and up to three 'secondary' harms were extracted, as these were considered to be the most important ones. Up to ten outcomes were thus extracted for each trial. Outcomes were defined as primary or secondary according to the description in the methods section of each article. Outcomes were considered beneficial or harmful when they were felt to be desired or to be avoided respectively. If a choice had to be made, the selection of harms and benefits for inclusion depended on clinical relevance, as determined by the reviewers. For example, a more patient‐relevant or patient‐reported outcome measure such as pain was preferred over surgical procedural outcomes such as perioperative pancreatojejunostomy leak. Outcomes, such as wound healing, that were assessed at various time points, were judged as a single outcome.

The various effect measures were recorded, including the accompanying precision measures, difference measures, precision measures of the differences between study arms, whether the outcomes were specifically defined and the time intervals of measurements.

Each extended CONSORT item was scored on a scale from 0 to 2 (0, no description; 1, inadequate description; 2, adequate description). Data were analysed using SPSS® version 22.0 (IBM, Armonk, New York, USA). A descriptive analysis was conducted for all available characteristics of the included journals and RCTs.

Results {#bjs550240-sec-0010}
=======

The search resulted in 9483 potentially eligible articles. Titles and abstracts from a random sample of 1200 articles were examined, from which 121 trials from nine different journals were included for full‐text screening. Of these, 88 articles were included in the final sample. An overview of the study selection and inclusion process is shown in *Fig*. [1](#bjs550240-fig-0001){ref-type="fig"}.

![PRISMA flow diagram of the study process](BJS5-4-171-g001){#bjs550240-fig-0001}

Characteristics of included journals {#bjs550240-sec-0011}
------------------------------------

The included 88 trials originated from six surgical and three general medical journals. Their characteristics are shown in *Table* [1](#bjs550240-tbl-0001){ref-type="table"}. Only the *Journal of Bone and Joint Surgery* did not explicitly endorse the CONSORT statement guidelines. The surgical and medical journals had median impact factors of 5·7 (range 4·3--8·6) and 44 (37·7--59·6) respectively.

Characteristics of included trials {#bjs550240-sec-0012}
----------------------------------

*Table* [3](#bjs550240-tbl-0003){ref-type="table"} provides an overview of the trial characteristics. Half of the 88 included trials were multicentre studies, the largest of which involved 177 centres. Of the 88 trials, 68 (77 per cent) compared a surgical intervention with another surgical intervention; the remaining 20 (23 per cent) compared a surgical intervention with a non‐surgical intervention.

###### 

Characteristics of included RCTs

                                                    No. of trials (*n* = 88)
  ------------------------------------------------ --------------------------
  **No. of centres**                                        88 (100)
  Single‐centre                                             44 (50)
  **Nature of intervention**                       
  Surgical *versus* surgical                                68 (77)
  Surgical *versus* non‐surgical                            20 (23)
  **Type of RCT**                                  
  Initial                                                   70 (80)
  Follow‐up                                                 18 (20)
  **Follow‐up period (months)**                    
  \< 1                                                       7 (8)
  1--5                                                      14 (16)
  6--12                                                     32 (36)
  \> 12                                                     34 (39)
  Missing                                                    1 (1)
  **Total no. of outcomes**                        
  1--3                                                      15 (17)
  4--6                                                      49 (56)
  7--9                                                      15 (17)
  10--12                                                     8 (9)
  13                                                         1 (1)
  **Measurement outcomes**                         
  Primary harm                                              54 (61)
  Primary benefit                                           39 (44)
  Secondary harm                                            70 (80)
  Secondary benefit                                         37 (42)
  **Statistician or epidemiologist involvement**   
  Involvement acknowledged                                  48 (55)
  **Funding**                                      
  No funding reported                                       17 (19)
  Possible impact of funding on results                     58 (66)
  Unrestricted grant stated                                 13 (15)
  **Mentioned adherence to CONSORT statement**               5 (6)

Values in parentheses are percentages.

Nearly 60 per cent of the included trials were conducted in Europe (*Fig*. [2](#bjs550240-fig-0002){ref-type="fig"}). *Fig*. [3](#bjs550240-fig-0003){ref-type="fig"} presents the subspecialties involved; gastrointestinal surgery (21 per cent), orthopaedic surgery (20 per cent) and vascular surgery (15 per cent) were involved most frequently. Adherence to the CONSORT statement was stated in 6 per cent of studies.

![Overview of the demographic distribution of included RCTs Count indicates the number of articles from each country.](BJS5-4-171-g002){#bjs550240-fig-0002}

![Overview of the subspecialties of included studies](BJS5-4-171-g003){#bjs550240-fig-0003}

A median of 6 (range 1--13) outcomes were reported in the included trials. A minority (39 of 88, 44 per cent) reported a primary benefit, in contrast to 54 trials (61 per cent) that stated a primary harm. In more than half of the trials (55 per cent) a statistician or epidemiologist was involved (*Table* [3](#bjs550240-tbl-0003){ref-type="table"}).

*Table* [*S1*](#bjs550240-supitem-0001){ref-type="supplementary-material"} (supporting information) presents detailed information for the included trials.

Reporting in included trials {#bjs550240-sec-0013}
----------------------------

The overall CONSORT scores of the included studies are shown in *Table* [1](#bjs550240-tbl-0001){ref-type="table"}. Median score was 49 (range 24--63) of 70. This score was slightly lower for surgical journals (median score 48 (24--63)) than for the general medical journals (median score 54 (38--63)). CONSORT scores were not significantly higher in more recent publications (median 42 for 2005--2011 *versus* 42·5 for 2012--2017 articles).

The metrics referring to harmful outcomes were reported inadequately in 33 of 88 studies (38 per cent) (*Table* [2](#bjs550240-tbl-0002){ref-type="table"}). Less than half of the studies were scored as adequate regarding the description of loss to follow‐up owing to the occurrence of harm. The description of plans for presenting and analysing information on harms was reported adequately in 61 per cent of the studies. The blinding process was poorly described. For example, only 24 trials (27 per cent) described blinding of the data analyst adequately (*Fig*. [4](#bjs550240-fig-0004){ref-type="fig"}). *Table* [2](#bjs550240-tbl-0002){ref-type="table"} shows that generalizability in the discussion section was reported adequately in only 11 per cent of the studies. In contrast, the definition of eligibility criteria was reported adequately in 99 per cent.

![Outcomes of the modified CONSORT checklist ](BJS5-4-171-g004){#bjs550240-fig-0004}

Reporting of outcome measurements {#bjs550240-sec-0014}
---------------------------------

An overview of the most frequently reported primary beneficial and harmful outcomes is given in *Table* [4](#bjs550240-tbl-0004){ref-type="table"}. In the 88 studies, a total of 46 primary beneficial outcomes and 63 primary harmful outcomes were reported. Every included study reported at least one discrete outcome. The most frequently reported primary beneficial outcome was a functional outcome measure (15 of 46 reported primary benefits), followed by a measure of the quality of life (10 of 46 benefits). Perioperative characteristics, for example operative blood loss (12 of 63 reported primary harms), complications (12 of 63 harms) and mortality (11 of 63 harms) were the most frequently reported primary harmful outcomes. Overall, 40 of all 280 reported outcomes (14·3 per cent) were not defined clearly. Definitions of primary benefits and harms were lacking in 11 per cent (5 of 46 benefits) and 10 per cent (6 of 63 harms) respectively.

###### 

Reporting of primary benefits and harms

                                                 No. of trials
  --------------------------------------------- ---------------
  **Primary benefits (*n* = 46)**               
  Functional patient‐reported outcome measure       15 (33)
  Quality of life                                   10 (22)
  Survival                                          5 (11)
  Intraoperative results                             4 (9)
  Technical success                                  4 (9)
  Overall success                                    4 (9)
  Remission                                          2 (4)
  Laboratory results                                 1 (2)
  Weight loss                                        1 (2)
  **Primary harms (*n* = 63)**                  
  Perioperative characteristics                     12 (19)
  Complications                                     12 (19)
  Mortality                                         11 (18)
  Pain                                              10 (16)
  Recurrence                                        7 (11)
  Self‐reported symptoms                             5 (8)
  Hospital stay                                      5 (8)
  Delay until return to work                         1 (2)

Values in parentheses are percentages.

*Tables* [5](#bjs550240-tbl-0005){ref-type="table"} and [6](#bjs550240-tbl-0006){ref-type="table"} present the effect and precision metrics for the reported benefits and harms. Overall, more trials reported continuous metrics (expressed as means or medians) than dichotomous measures (such as percentages or absolute numbers). In 29 (63 per cent) of the 46 trials in which primary benefits were described, these were continuous outcomes. Only eight (8 per cent) of the 99 primary and secondary beneficial outcomes were reported as percentages with the corresponding absolute numbers, and 13 per cent (13 of 99) were reported as percentages only (*Table* [5](#bjs550240-tbl-0005){ref-type="table"}).

###### 

Frequency of reported outcomes and precision metrics on benefits of trials

                                              Primary benefit 1 (*n* = 39)   Primary benefit 2 (*n* = 7)   Secondary benefit 1 (*n* = 37)   Secondary benefit 2 (*n* = 13)   Secondary benefit 3 (*n* = 3)
  ------------------------------------------ ------------------------------ ----------------------------- -------------------------------- -------------------------------- -------------------------------
  **Effect measure**                                                                                                                                                        
  Missing                                                1 (3)                           --                              --                               --                              --
  Mean                                                  19 (49)                        5 (71)                         21 (57)                           9 (69)                          1 (33)
  Median                                                 4 (10)                        1 (14)                          7 (19)                           2 (15)                          2 (67)
  Percentage                                             6 (15)                        1 (14)                          6 (16)                             --                              --
  Absolute number                                        2 (5)                           --                            2 (5)                            1 (8)                             --
  Absolute number + percentage                           6 (15)                          --                            1 (3)                            1 (8)                             --
  Mean and median                                        1 (3)                           --                              --                               --                
  **Precision measure of effect**                                                                                                                                           
  Missing                                               13 (33)                          --                           10 (27)                           4 (31)                            --
  *P* value                                              1 (3)                         1 (14)                            --                               --                              --
  95 per cent c.i.                                       6 (15)                          --                            9 (24)                           3 (23)                            --
  s.d.                                                  15 (39)                        5 (71)                         12 (32)                           4 (31)                          1 (33)
  i.q.r.                                                 2 (5)                         1 (14)                          4 (11)                           2 (15)                          2 (67)
  s.d. and i.q.r.                                        1 (3)                           --                              --                               --                              --
  Range                                                  1 (3)                           --                            2 (5)                              --                              --
  **Difference measure**                                                                                                                                                    
  Missing                                                3 (8)                           --                            1 (3)                            1 (8)                             --
  Risk ratio                                             1 (3)                           --                              --                               --                              --
  Hazard ratio                                           4 (10)                        1 (14)                          1 (3)                              --                              --
  Odds ratio                                             2 (5)                           --                            1 (3)                              --                              --
  Difference in mean                                    16 (41)                        4 (57)                         18 (49)                           6 (46)                          1 (33)
  Difference in percentage                               3 (8)                           --                            5 (14)                             --                            2 (67)
  Difference in median                                   4 (10)                        1 (14)                          7 (19)                           2 (15)                            --
  Difference in absolute number                            --                            --                            2 (5)                            1 (8)                             --
  General effect size                                    2 (5)                         1 (14)                          1 (3)                            2 (15)                            --
  Risk difference                                        2 (5)                           --                            1 (3)                            1 (8)                             --
  Relative risk and number needed to treat               1 (3)                           --                                                               --                              --
  Difference in mean and in median                       1 (3)                           --                              --                               --                              --
  **Precision measure of difference**                                                                                                                                       
  *P* value                                             23 (59)                        5 (71)                         27 (73)                           9 (69)                          3 (100)
  95 per cent c.i.                                       1 (3)                         1 (14)                          3 (8)                            1 (8)                             --
  *P* value and 95 per cent c.i.                        14 (36)                        1 (14)                          7 (19)                           3 (23)                            --
  90 per cent c.i.                                       1 (3)                           --                              --                               --                              --

Values in parentheses are percentages.

###### 

Reporting outcomes and precision metrics on harms

                                                            Primary harm 1 (*n* = 54)   Primary harm 2 (*n* = 9)   Secondary harm 1 (*n* = 70)   Secondary harm 2 (*n* = 33)   Secondary harm 3 (*n* = 15)
  -------------------------------------------------------- --------------------------- -------------------------- ----------------------------- ----------------------------- -----------------------------
  **Effect measure**                                                                                                                                                          
  Missing                                                             1 (2)                        --                          --                           2 (6)                          --
  Mean                                                               19 (35)                     4 (44)                      12 (17)                       8 (24)                        2 (13)
  Median                                                             7 (13)                        --                        7 (10)                         3 (9)                        2 (13)
  Percentage                                                         8 (15)                      1 (11)                      7 (10)                        5 (15)                        2 (13)
  Absolute number                                                     3 (6)                        --                        12 (17)                       7 (21)                        3 (20)
  Absolute number + percentage                                       15 (28)                     3 (33)                      30 (43)                       8 (24)                        5 (33)
  Cumulative incidence                                                1 (2)                      1 (11)                        --                            --                            --
  Absolute number + mean                                               --                          --                         1 (1)                          --                            --
  Ratio                                                                --                          --                         1 (1)                          --                            --
  Rate/100 patient‐years                                               --                          --                          --                            --                           1 (7)
  **Precision measure of effect**                                                                  --                                                                         
  Missing                                                            23 (43)                     4 (44)                      46 (66)                       21 (64)                       10 (67)
  *P* value                                                           1 (2)                        --                         1 (1)                         1 (3)                         1 (7)
  95 per cent c.i.                                                   6 (11)                      1 (11)                       6 (9)                         1 (3)                           ‐
  s.d.                                                               13 (24)                     4 (44)                      9 (13)                        6 (18)                        1 (13)
  i.q.r.                                                              1 (2)                        --                         2 (3)                          --                           1 (7)
  Range                                                               5 (9)                        --                         4 (6)                        4 (12)                         1 (7)
  *P* value and range                                                 1 (2)                        --                         1 (1)                          --                            --
  s.e.m.                                                              3 (6)                        --                         1 (1)                          --                            --
  **Difference measure**                                                                                                                                                      
  Missing                                                             4 (7)                      1 (11)                      19 (27)                       10 (30)                       4 (27)
  Risk ratio                                                          4 (7)                      1 (11)                       1 (1)                          --                            --
  Hazard ratio                                                       7 (13)                        --                         2 (3)                         1 (3)                          --
  Odds ratio                                                          4 (7)                      1 (11)                       2 (3)                         1 (3)                          --
  Difference in mean                                                 18 (33)                     4 (44)                      13 (19)                       8 (24)                        2 (13)
  Difference in percentage                                           7 (13)                        --                        26 (37)                       9 (27)                        6 (40)
  Difference in median                                               7 (13)                        --                         5 (7)                         3 (9)                        2 (13)
  Risk difference                                                     3 (6)                      1 (11)                       1 (1)                         1 (3)                          --
  Difference in cumulative incidence                                   --                        1 (11)                        --                            --                            --
  Effect size                                                          --                          --                         1 (1)                          --                            --
  Difference in rate/100 patient‐years                                 --                          --                          --                            --                           1 (7)
  **Precision measure of difference**                                                                                                                                         
  Missing                                                             3 (6)                      1 (11)                      11 (16)                       5 (15)                        2 (13)
  *P* value                                                          29 (54)                     4 (44)                      51 (73)                       25 (76)                       13 (87)
  95 per cent c.i.                                                   6 (12)                        --                         1 (1)                          --                            --
  *P* value and 95 per cent c.i.                                     14 (26)                     4 (44)                       6 (9)                         3 (9)                          --
  90 and 95 per cent c.i.                                             1 (2)                        --                         1 (1)                          --                            --
  *P* value, 95 per cent c.i. and number needed to treat              1 (2)                        --                          --                            --                            --

Values in parentheses are percentages.

A total of 63 primary and 118 secondary harms were reported. In 48 per cent of the trials the primary harm was a continuous outcome. Of the 181 primary and secondary harmful outcomes, 61 (33·7 per cent) were reported as percentages with the corresponding absolute numbers, and 23 (12·7 per cent) were reported as percentages only (*Table* [6](#bjs550240-tbl-0006){ref-type="table"}).

The precision of the observed differences was usually reported as a *P* value only, and not as a 95 per cent confidence interval. For the differences in effect size of beneficial outcomes, 68 per cent of the trials reported a *P* value only, and not a 95 per cent confidence interval. For harmful effects, this was 67 per cent.

Only five of the 88 studies (6 per cent) mentioned a NNT or NNH. However, a NNT or NNH could be calculated based on the absolute numbers provided for eight of the 46 documented primary benefit outcomes, and for two of the 63 reported primary harm outcomes. Some 39 per cent of the trials did not report on both the beneficial and harmful outcomes of the intervention studied in the same paper.

Discussion {#bjs550240-sec-0015}
==========

This systematic review analysed the reporting of data from surgical RCTs published within the past two decades in leading surgical and medical journals. The CONSORT statements have been designed to optimize the reporting of (benefits and harms in) trials, but this review found that current publications still show suboptimal reporting of discrete data. Previous systematic reviews have addressed the suboptimal level of adherence to the CONSORT statement in publications in surgical journals[13](#bjs550240-bib-0013){ref-type="ref"}. The present review adds to this in terms of deficiencies in how data on benefits and harms are reported. Few of these outcomes were described as an adequate and easily interpretable effect estimate or difference measure. Measures of precision such as confidence intervals were missing in most trial reports. In combination with effect size, precision measures help the reader to appreciate whether or not a finding is clinically relevant. Besides effect and precision measures, benefits and harms should be defined clearly so that healthcare providers can communicate these with patients.

Most trials included in this review provided *P* values only, which express statistical significance[14](#bjs550240-bib-0014){ref-type="ref"} but do not communicate unequivocally the amount of statistical uncertainty that surrounds the available effect estimate. *P* values can make it more difficult to appreciate results, with risks of misinterpretation and errors in assessing the applicability of an intervention in clinical practice[15](#bjs550240-bib-0015){ref-type="ref"}.

More trials in the present review reported on harms than on benefits as primary outcomes. This finding is in contrast with a previous review that showed poor reporting of harms[16](#bjs550240-bib-0016){ref-type="ref"}. Possibly, trials of surgical interventions pay more (but still insufficient) attention to harmful effects, given the invasive nature of the intervention.

The number of patients who need to be treated to achieve one additional beneficial event, the NNT, has become a well known measure of treatment benefit[11](#bjs550240-bib-0011){ref-type="ref"}. When treatment decisions are to be made, particularly in the surgical outpatient clinic, these parameters may help healthcare providers explain to their patients the expected benefits and risks of interventions. Back in 2001, the CONSORT statement argued that the NNT could be helpful to express the results of an RCT.

Studies assessing reporting quality before the extended CONSORT statement was issued[17](#bjs550240-bib-0017){ref-type="ref"}, [18](#bjs550240-bib-0018){ref-type="ref"} showed similar shortcomings. Unfortunately, the publications evaluated here still suffered from the same shortcomings, despite the fact that leading medical journals have supported the recommendations for standards of reporting[11](#bjs550240-bib-0011){ref-type="ref"}, [17](#bjs550240-bib-0017){ref-type="ref"}, [19](#bjs550240-bib-0019){ref-type="ref"}, or even extended them[20](#bjs550240-bib-0020){ref-type="ref"}. Generalizability of the results was described poorly in most trials. This aspect is crucial for healthcare providers to appreciate whether the results of a trial are relevant and applicable to their own patient population.

The present review has limitations. Of the 88 trials included in the analysis, 18 were follow‐up studies, in which some primary reports of trial results were not included. As these follow‐up studies often did not describe further details about trial designs and methods, this might have resulted in a lower modified CONSORT score in comparison with the initial RCTs. However, when reporting follow‐up data of a study, authors should make clear the main points of the methodology and outcomes of the conducted RCT. The random sample did not yield studies from all initially selected journals, although this seems unlikely to have influenced the findings, as all studies were published in leading journals, nearly all of which endorsed the CONSORT statement. It was, however, unclear in which year the journals in the survey adopted this requirement in their instructions to authors. This study was limited to studies of surgical *versus* surgical *versus* non‐surgical interventions. Surgical trials reporting on non‐surgical interventions alone might show higher CONSORT scores, because non‐surgical (mostly drug) treatments tend to be better scrutinized and monitored before reporting the outcomes. The classification of outcomes as beneficial or harmful was sometimes ambiguous. For example, pain is generally interpreted as harmful and was therefore reported as 'harm', but in one study[21](#bjs550240-bib-0021){ref-type="ref"} reduction in pain was scored as a 'benefit'.

The CONSORT statement, along with the extension for harms, provides guidelines that should ensure high reporting quality for RCTs. Current trials, however, reported in leading surgical and medical journals still fail to describe reported benefits and harms in surgical RCTs correctly, despite the fact that the CONSORT statement is supported widely. Interpretation of the provided evidence remains difficult and susceptible to interpretation bias, which, in turn, impedes adoption. Authors, editors, statisticians and peer reviewers should emphasize adherence to CONSORT guidelines to facilitate evidence‐based clinical decision‐making.
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